The Influence of Autologous Bone Marrow Stem Cell Transplantation on Matrix Metalloproteinases in Patients Treated for Acute ST-Elevation Myocardial Infarction
Table 1
Characteristics of the study population according to the randomized groups. Values are presented as proportion, means ± SD, or medians1 with 25th and 75th percentiles.
mBMC group ()
Control group ()
Age (years)
58.1 (8.6)
56.7 (9.6)
Gender (% female)
16
16
Hypertension (%)
35
34
Diabetes (%)
10
8
Smokers (%)
39
48
BMI (kg/m2)
26.3 (3.3)
27.1 (4.1)
SBP/DBP (mmHg)
131/82 ± 21/14
132/83 ± 23/17
Tot. chol (mmol/L)
4.4 ± 0.9
4.5 ± 0.9
LDL chol (mmol/L)
2.9 ± 0.8
2.9 ± 0.7
HDL chol (mmol/L)
1.0 ± 0.3
1.1 ± 0.3
Triglycerides (mmol/L)1
1.3 (1.0, 1.7)
1.3 ± (1.1, 1.5)
Symptom start to PCI (min)1
210 (180, 330)
230 (180, 330)
LVEF (%)
41.3 (10.6)
42.6 (11.7)
Infarct size (%)
43.7 ± 17.6
40.7 ± 19.3
Peak CK (U/L)
3338 ± 2398
3532 ± 2650
Thrombolysis before PCI (%)
30
28
Medication at discharge
Aspirin (%)
100
100
Clopidogrel (%)
100
100
ACE-I/ATII antagonist (%)
100
100
-blocker (%)
100
100
Diuretics (%)
43
32
Statin (%)
100
100
ATII antagonist: angiotensin II receptor antagonist; ACE-I: angiotensin-converting enzyme inhibitor; BMI: body mass index; DBP: diastolic blood pressure; LVEF: left ventricular ejection fraction; PCI: percutaneous coronary intervention; and SBP: systolic blood pressure.
